trial

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

NCTId NCT02442817
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 10 (actual)
Sponsored by University of Nevada, Reno
Primary completion 2018-03-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
10 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2015-03-02
Primary completion
2018-03-02
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Linagliptin

Sponsors

University of Nevada, RenoLead Sponsor
Augusta UniversityCollaborator

Investigators

1
Brian Kirkpatrick, MDPrincipal Investigator

Sites

1 total
Reno, United States

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE4
Primary Completion Date
2018-03-02
Status
COMPLETED
relationships
The graph out of here
drug
Linagliptin
drug
lead_sponsor
University of Nevada, Reno
company
collaborator
Augusta University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Brian Kirkpatrick, MD
person